Associated tags: Hypertriglyceridemia, PSC, Orphan drug, HighTide, Type 2 diabetes, NASH, Primary sclerosing cholangitis, T2DM, Fatty liver disease, Fast Track, Pharmaceutical industry, Patient, Biotechnology, Health, Pharmaceutical, Therapy, NAFLD, Clinical Trials, Primary biliary cholangitis, General Health, Institute of Liver and Biliary Sciences, Diabetes, Roy Taylor (scientist)
Locations: BAHRAIN, IRAN, IRAQ, JORDAN, KUWAIT, LEBANON, OMAN, PALESTINE, QATAR, SAUDI ARABIA, SYRIA, UNITED ARAB EMIRATES, YEMEN, MARYLAND, MIDDLE EAST, CHINA
Berberine,
Ageing,
Attention,
Future Investment Initiative Institute,
AMPK,
Conference,
Research,
Type 2 diabetes,
FII,
Ursodeoxycholic acid,
NME,
Quality of life,
HighTide,
NASH,
Insulin resistance,
AI,
Therapy,
Patient,
T2DM,
Fatty liver disease,
Pharmaceutical industry The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.
Key Points:
- The rising burden of aging-related diseases has become an urgent global health challenge that requires immediate attention.
- Recent advances in anti-aging research and big data empower a more holistic approach to understanding and reversing human aging with evidence suggests that slowing down aging can substantially improve quality of life.
- The FII Conference, hosted by the Future Investment Initiative (FII) Institute, has been held for seven consecutive years and has developed into one of the most important economic and investment forums in the Middle East.
- This year's conference (FII7) was attended exclusively by FII Institute members, strategic partners, decision-makers, and international leaders, and is expected to draw 5,000 delegates attending sessions covering a wide variety of issues with global impact.
Retrieved on:
Wednesday, January 11, 2023
Retrieved on:
Wednesday, January 11, 2023
Liver injury,
NAFLD,
Cirrhosis,
Glycated hemoglobin,
Lipid,
Prediabetes,
Risk,
BID,
Chronic liver disease,
Patient,
Fatty liver disease,
HighTide,
Fibrosis,
Liver disease,
NASH,
Injury,
T2DM,
Medical imaging,
MD ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
Key Points:
- ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
- This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to placebo BID on histologic improvement in adult subjects with NASH and liver fibrosis who also have type 2 diabetes mellitus ("T2DM") or pre-diabetes.
- The study will enroll approximately 210 subjects with biopsy-confirmed NASH and evidence of stage 2 or stage 3 liver fibrosis.
- "Nonalcoholic fatty liver disease ("NAFLD") is the most prevalent chronic liver disease worldwide with a global prevalence of 25.2% to 29.8%.
Retrieved on:
Thursday, January 5, 2023
Retrieved on:
Thursday, January 5, 2023
T2DM,
Food,
Venture round,
PSC,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Primary sclerosing cholangitis,
NASH,
Trial of the century,
Series,
HighTide,
Patient,
Fatty liver disease,
FDA,
Pharmaceutical industry,
MD Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
Key Points:
- Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
- "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
- "The Series C/C+ financing is a significant milestone for HighTide.
- It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."
Retrieved on:
Tuesday, October 25, 2022
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Clinical Trials,
Dysbiosis,
Risk,
Therapy,
Non-alcoholic fatty liver disease,
T2DM,
American Association for the Study of Liver Diseases,
Population,
Gut microbiota,
Cholestasis,
Alkaline phosphatase,
Lists of diseases,
Liver injury,
Primary sclerosing cholangitis,
HIV disease progression rates,
Fatty liver disease,
Orphan drug,
NASH,
Liver,
AASLD,
HighTide,
American Association,
Association,
2021 Essex County Council election,
Fast Track,
ALP,
PSC,
Institute of Liver and Biliary Sciences,
Pharmaceutical industry,
Dietary supplement,
Patient HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
Key Points:
- HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
- Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
- Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
- Presentations at the Liver Meeting 2022 include:
We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.
Retrieved on:
Thursday, October 20, 2022
Health,
General Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
San Diego State University,
Therapy,
T2DM,
Business administration,
Master of Business Administration,
Primary sclerosing cholangitis,
Business,
Fatty liver disease,
Orphan drug,
Senior,
Partnership,
NASH,
Ionis Pharmaceuticals,
HighTide,
Novartis,
Apricus Biosciences,
CEO,
Business development,
Fast Track,
Conatus,
Head,
PSC,
Solution,
Greater China,
Program,
Pharmaceutical industry,
Management,
Microbiology HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
Key Points:
- HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
- Mr. Ripley has 25 years of experience in pharmaceutical business development.
- Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles.
- Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals.
Biotechnology,
Diabetes,
Health,
Pharmaceutical,
Clinical Trials,
Cardiovascular disease,
Mortality,
Diabetes,
Chinese,
COVID-19,
HIV disease progression rates,
Glycated hemoglobin,
CEO,
Non-alcoholic fatty liver disease,
Safety,
Dyslipidemia,
Obesity,
Liver,
Therapy,
Roy Taylor (scientist),
Institute of Liver and Biliary Sciences,
Time,
A1C,
Disease,
Death,
Decision-making,
Risk,
HighTide,
Fatty liver disease,
Cirrhosis,
Hepatocellular carcinoma,
Department,
Prognosis,
Glycemia,
Kidney disease,
Goal,
Peking University,
Type 2 diabetes,
Hospital,
Prevalence,
Hypertension,
Comorbidity,
NASH,
Biomarker,
Adult,
T2DM,
End organ damage,
Patient,
Pharmaceutical industry,
NAFLD,
Hyperuricemia,
Endocrinology HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
Key Points:
- HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
- The study enrolled 113 subjects, and the endpoints include the change in hemoglobin A1c (HbA1c) after 12 weeks of treatment as well as changes in biomarkers of NAFLD.
- Previous Phase 2 study in adults with comorbid nonalcoholic steatohepatitis (NASH) and T2DM completed in the United States demonstrated overall clinical benefits across liver, lipid, glycemia, weight, metabolic, and cardiovascular health.
- The multi-functional HTD1801 developed by HighTide aims to provide patients with broad clinical benefit across glycemia, liver, and cardiovascular health.
Biotechnology,
Diabetes,
Health,
Pharmaceutical,
Clinical Trials,
Adult,
A1C,
CEO,
Fatty liver disease,
Roy Taylor (scientist),
Association,
Patient,
Glycated hemoglobin,
Hypertriglyceridemia,
Incidence,
Therapy,
Cirrhosis,
Cardiovascular disease,
HighTide,
Liver,
Prevalence,
Primary sclerosing cholangitis,
Primary biliary cholangitis,
Insulin resistance,
Hepatocellular carcinoma,
Trial of the century,
NASH,
Risk,
NAFLD,
Population,
Safety,
Pharmaceutical industry,
T2DM HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
Key Points:
- HighTide Therapeutics, Inc. (HighTide), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
- T2DM and NAFLD remain the most common chronic diseases worldwide with rapidly increasing prevalence and incidence.
- Given the strong association and overlapping pathophysiology, there is a sizable population of patients with comorbid T2DM and NAFLD.
- The complex pathophysiology of T2DM and NAFLD requires the engagement of multiple mechanistic pathways to optimize pharmacological intervention.
Biotechnology,
General Health,
Pharmaceutical,
Health,
Drug development,
BioMarin Pharmaceutical,
Therapy,
University,
Primary biliary cholangitis,
Degenerative disease,
Master of Science,
Institute of Liver and Biliary Sciences,
Regulatory affairs,
Quality assurance,
Cholestasis,
Primary sclerosing cholangitis,
Pregnancy,
Biliary atresia,
Medicinal chemistry,
University of California, San Diego,
HighTide,
Cholestatic pruritus,
Senior,
Cell biology,
T2DM,
Alagille syndrome,
Clinical trial,
Hypertriglyceridemia,
Patient,
Pharmaceutical industry,
Biochemistry,
Science,
Spiroplasma mirum HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
Key Points:
- HighTide Therapeutics, Inc. (HighTide), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
- Mrs. Leoncavallo will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.
- We are very pleased to welcome Myleen to HighTide, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.
- Prior to Mirum, Mrs. Leoncavallo served in several senior regulatory affairs roles, including positions at Ultragenyx Pharmaceuticals and BioMarin Pharmaceuticals, biopharmaceutical companies focused on rare diseases.